Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- 1 May 2015
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 385 (9982) , 2057-2066
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO studyDiabetes, Obesity and Metabolism, 2011
- Comparison of insulin detemir and insulin glargine using a basal‐bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetesDiabetes/Metabolism Research and Reviews, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClinical Therapeutics, 2008
- General Multistage Gatekeeping ProceduresBiometrical Journal, 2008
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group studyClinical Therapeutics, 2008
- Adjust to Target in Type 2 DiabetesDiabetes Care, 2008
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005